Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Cancer Biomarker Found?

By Drug Discovery Trends Editor | September 25, 2013

The FGFR2b receptor has proved to play an important role in certain types of breast cancer. In this image, the receptor is red. (Source: University of Copenhagen)New insights into the molecular mechanisms of cancer cell growth and metastasis may lead to improved and more targeted drugs, according to researchers at the University of Copenhagen. 
 
Researchers are constantly trying to learn more about the body’s advanced communication processes. Receptors serve as a kind of switchboard in the cell, which connects specific signaling proteins to specific cellular functions. Using state-of-the-art technology, researchers at University of Copenhagen have studied a special cell surface receptor of major importance for health and disease. 
 
“We have pinpointed the binding site that can cause increased spreading of breast cancer cells and thus the development of metastases,” said protein researcher Jesper Velgaard Olsen, Professor at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen.
 
“We have studied two cellular signaling proteins with each their widely different biological influence on the so-called FGFR2b receptor. One of the proteins is involved in cell division, whereas the other controls cell movement. Both processes are important for a healthy cell, but if they spin out of control it may have serious implications, e.g. in the form of cancer cell growth and development of metastases,” said Olsen.
 
The findings have just been published in the scientific journal Molecular Cell.
 
The FGFR2b receptor is co-responsible for the optimal development of inner organs at the embryonic stage, in particular lung tissue. A dysfunction in the receptor’s signal therefore has serious implications for normal lung tissue function. The receptor has also proved to play an important role in certain types of breast cancer.
 
Better drugs in the future
The new research is based on human cancer cells and murine tissue but may, in the long run, help improve the customised treatment of, e.g., breast cancer in humans:
 
The FGFR2b receptor has proved to play an important role in certain types of breast cancer.
 
“Doctors currently use special biomarkers for diagnosing and treating cancers. The FGFR2b receptor may in the future serve as a new biomarker. The more we know about the body’s transmission systems, the better we become at targeting medical treatment. Hopefully, we will in future be able to offer customised treatment based on the individual patient’s cellular profile,” said Olsen.
 
The researchers have used state-of-the-art technology within protein research at The Novo Nordisk Foundation Center for Protein Research:
 
“Using advanced mass spectrometry allows us to study cellular proteins in such detail that was previously only possible within the field of genetics. It was previously a huge challenge to analyze proteins – but today we can study thousands of proteins in a very short time”, said Olsen.
 
 
Date: September 25, 2013
Source: University of Copenhagen

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE